Glaxo paid $3 billion in fines to settle allegations of fraud regarding this diabetes drug |
- GWC
by Katie Thomas - New York Times
The British drug maker GlaxoSmithKline will no longer pay doctors to promote its products and will stop tying compensation of sales representatives to the number of prescriptions doctors write, its chief executive said Monday, effectively ending two common industry practices that critics have long assailed as troublesome conflicts of interest.
No comments:
Post a Comment